These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1140 related items for PubMed ID: 15876287

  • 1. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P, Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [Abstract] [Full Text] [Related]

  • 2. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [Abstract] [Full Text] [Related]

  • 3. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C, Lee S, Wong Kh, Cheng L, Lam M.
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [Abstract] [Full Text] [Related]

  • 4. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort.
    Antivir Ther; 2007 Apr; 12(6):941-7. PubMed ID: 17926648
    [Abstract] [Full Text] [Related]

  • 5. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 6. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group.
    Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251
    [Abstract] [Full Text] [Related]

  • 7. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

  • 8. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
    Kaplan JE, Hanson DL, Cohn DL, Karon J, Buskin S, Thompson M, Fleming P, Dworkin MS, Adult and Adolescent Spectrum of HIV Disease Project Investigators.
    Clin Infect Dis; 2003 Oct 01; 37(7):951-8. PubMed ID: 13130408
    [Abstract] [Full Text] [Related]

  • 9. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
    Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS.
    AIDS; 2006 Feb 14; 20(3):371-7. PubMed ID: 16439870
    [Abstract] [Full Text] [Related]

  • 10. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.
    J Infect Dis; 2007 Oct 01; 196(7):1044-52. PubMed ID: 17763327
    [Abstract] [Full Text] [Related]

  • 11. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 12. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S, Alary M.
    HIV Med; 2009 Nov 13; 10(10):640-6. PubMed ID: 19659945
    [Abstract] [Full Text] [Related]

  • 13. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.
    Onen NF, Overton ET, Presti R, Blair C, Powderly WG, Mondy K.
    HIV Med; 2009 Aug 13; 10(7):439-46. PubMed ID: 19459993
    [Abstract] [Full Text] [Related]

  • 14. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL.
    Moore DM, Hogg RS, Yip B, Craib K, Wood E, Montaner JS.
    HIV Med; 2006 Sep 13; 7(6):383-8. PubMed ID: 16903983
    [Abstract] [Full Text] [Related]

  • 15. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.
    HIV Med; 2006 Mar 13; 7(2):99-104. PubMed ID: 16420254
    [Abstract] [Full Text] [Related]

  • 16. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN.
    J Infect Dis; 2004 Nov 15; 190(10):1860-8. PubMed ID: 15499544
    [Abstract] [Full Text] [Related]

  • 17. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.
    Antivir Ther; 2003 Oct 15; 8(5):379-84. PubMed ID: 14640384
    [Abstract] [Full Text] [Related]

  • 18. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 19. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD, EuroSIDA study group.
    HIV Med; 2007 Mar 13; 8(2):96-104. PubMed ID: 17352766
    [Abstract] [Full Text] [Related]

  • 20. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B, MANIF 2000 Study Group.
    Antivir Ther; 2005 Mar 13; 10(1):53-61. PubMed ID: 15751763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.